Over the past three decades, the enhanced permeability and retention (EPR) effect has
been considered the basis of tumor-targeted drug delivery. Various cancer nanomedicines …

The blood-brain barrier (BBB) constitutes a microvascular network responsible for excluding
most drugs from the brain. Treatment of brain tumors is limited by the impermeability of the …

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent
neurodegenerative diseases, affecting millions and costing billions each year in the United …

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Loss-of-function heterozygous mutations in GRN, the gene encoding progranulin (PGRN),
were identified in patients with frontotemporal lobar degeneration (FTLD) almost two …

Ultrasmall nanoparticles are often grouped under the broad umbrella term of “nanoparticles”
when reported in the literature. However, for biomedical applications, their small sizes give …

Protein-based therapeutics are an attractive alternative to established therapeutic
approaches and represent one of the fastest growing families of drugs. While many of these …

The blood–brain barrier (BBB) plays a vital role in the protection and maintenance of
homeostasis in the brain. In this way, it is an interesting target as an interface for various …

Monoclonal antibodies (mAbs) hold promise in treating Parkinson's disease (PD), although
poor delivery to the brain hinders their therapeutic application. In the current study, it is …

Since the 2013 Nobel Prize was awarded for the discovery of vesicle trafficking, a subgroup
of nanovesicles called exosomes has been driving the research field to a new regime for …